Vol.
36
No.
2
February 22, 2013Feb 22, 2013
Free

Abraxane Combination Improves Survival In Treatment-Naïve Metastatic Disease

Avastin Increases Overall Survival 3.7 Months

First-Line Bendamustine Doubles PFS In Non-Hodgkin and Mantle Cell Lymphoma

Phase III Trial of ThermoDox Fails to Meet Primary Endpoint

Neulasta Reduces Incidence Of Febrile Neutropenia

Tivozanib Does Not Improve OS Compared to Sorafenib

In Surgery vs Radiotherapy, Outcome Differences Equalize After 15 Years Follow-up

Genomic Test More Accurate In Predicting Metastasis Than PSA, Tumor Stage & Grade

Protein May Link Obesity To Cancer Aggressiveness

“Triple-Negative” Should Be Split Into Subtypes, Say Researchers

NCI CTEP Approved Trials For the Month of February

Avastin Combination Approved For Metastatic Colorectal Cancer

FDA Grants Priority Review To Two Drugs in NSCLC

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login